Companies
Armata Pharmaceuticals
AP-SA02, an IV phage cocktail dosed alongside standard antibiotics for complicated S. aureus bacteremia, read out positive Phase 2a data in May 2025, received FDA Qualified Infectious Disease Product designation,…
- Country
- United States
- Ticker
- ARMP
Clinical
Coverage
| CN | EU | US | |
|---|---|---|---|
| therapeutics-platforms | ✓ | ✓ | ✓ |
Regulatorsfdaemanmpa
Verifiable facts
| Fact | Value | Source |
|---|---|---|
| Funding | $28.7 million total funding from Department of Defense (DoD) award for AP-SA02 development | armatapharma.com · sec.gov |
| Capacity | over 10,000 full courses of phage therapy annually | sec.gov |
| Regulatory approval | Qualified Infectious Disease Product (QIDP) and Fast Track designations for AP-SA02 | armatapharma.com · prnewswire.com · sec.gov |
| Production site | cGMP manufacturing facility in Los Angeles, California | prnewswire.com · sec.gov |
| Revenue | $4.9 million in grant and award revenue for the year ended December 31, 2025 | prnewswire.com · sec.gov |
Independent sources: prnewswire.com · sec.gov
Technologies
| Name | Cluster | Risk | |
|---|---|---|---|
| Bacteriophage therapy | therapeutics-platforms | High | → |
Compiled by BIOECON from primary sources.
Compliance
Bioecon is an information intermediary; it is not a regulator, a certification body, or a legal advisor. When working with public-sector customers (procurement under 44-FZ / 223-FZ), Bioecon acts solely as an independent analytical platform, with no remuneration from suppliers.